Difference between revisions of "Part:BBa K5059000"
| Line 4: | Line 4: | ||
This sequence resembles the MdOSC1 variant of the alpha-amyrin synthase from ''Malus domestica''. Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway [1]. Since ''S. cerevisiae'' doesn't contain AAS, we integrated this sequence into its genome to successfully produce ursolic acid. We codon-optimized the sequence using Benchling to be compatible with iGEM Assembly Standards. We also attached a 6xHis tag at the end of the sequence to enable Ni-NTA affinity chromatography for convenient enzyme isolation. | This sequence resembles the MdOSC1 variant of the alpha-amyrin synthase from ''Malus domestica''. Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway [1]. Since ''S. cerevisiae'' doesn't contain AAS, we integrated this sequence into its genome to successfully produce ursolic acid. We codon-optimized the sequence using Benchling to be compatible with iGEM Assembly Standards. We also attached a 6xHis tag at the end of the sequence to enable Ni-NTA affinity chromatography for convenient enzyme isolation. | ||
| − | |||
===Sequence and Features=== | ===Sequence and Features=== | ||
| Line 15: | Line 14: | ||
<!-- --> | <!-- --> | ||
| + | <!-- Add more about the biology of this part here | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
Ursolic acid has gained traction recently as a potential therapeutic agent. Preliminary studies have been done on ursolic acid, determining its therapeutic potential for cancer, liver disease, and obesity, among other health benefits [2]. There is particular interest in ursolic acid's properties in fighting cancer, as it is an antioxidant and anti-inflammatory agent. Clinical trials are currently underway to test its use in cancer-treating drugs. However, the current method for ursolic acid extraction from fruits, such as apples and loquats, is inefficient, environmentally taxing, and expensive. By engineering ''S. cerevisiae'' to produce ursolic acid, the traditional method for its extraction can be bypassed by utilizing the pathway shown below. | Ursolic acid has gained traction recently as a potential therapeutic agent. Preliminary studies have been done on ursolic acid, determining its therapeutic potential for cancer, liver disease, and obesity, among other health benefits [2]. There is particular interest in ursolic acid's properties in fighting cancer, as it is an antioxidant and anti-inflammatory agent. Clinical trials are currently underway to test its use in cancer-treating drugs. However, the current method for ursolic acid extraction from fruits, such as apples and loquats, is inefficient, environmentally taxing, and expensive. By engineering ''S. cerevisiae'' to produce ursolic acid, the traditional method for its extraction can be bypassed by utilizing the pathway shown below. | ||
Revision as of 15:40, 1 October 2024
Alpha-Amyrin Synthase (AAS)
This sequence resembles the MdOSC1 variant of the alpha-amyrin synthase from Malus domestica. Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway [1]. Since S. cerevisiae doesn't contain AAS, we integrated this sequence into its genome to successfully produce ursolic acid. We codon-optimized the sequence using Benchling to be compatible with iGEM Assembly Standards. We also attached a 6xHis tag at the end of the sequence to enable Ni-NTA affinity chromatography for convenient enzyme isolation.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]